International audienceImmunization with the live-attenuated Yersinia pseudotuberculosis VTnF1 strain producing a Yersinia pestis F1 pseudocapsule efficiently protects mice against bubonic and pneumonic plague. In clinical trials, demonstration of a plague vaccine's efficacy in humans will not be feasible, and correlates of protection will be needed to bridge the immune response of protected animals to that of vaccinated humans. Using serum transfer and vaccination of antibody-deficient µMT mice, we established that both humoral and cellular responses elicited by VTnF1 independently conferred protection against bubonic plague. Thus, correlates were searched for in both responses, using blood only. Mice were vaccinated with increasing doses o...
AbstractLive plague vaccines have saved thousands of human lives in the 20th century and have contin...
Relatively recent advances in plague vaccinology have produced the recombinant fusion protein F1-V p...
Abstract. A single, subcutaneous, 30-mg dose of either a combination of the Yersinia pestis proteins...
International audienceImmunization with the live-attenuated Yersinia pseudotuberculosis VTnF1 strain...
<div><p>Background</p><p>No efficient vaccine against plague is currently available. We previously s...
International audienceWe evaluated the possibility of using Yersinia pseudotuberculosis as a live va...
Yersinia pestis is the etiologic agent of plague that has killed more than 200 million people throug...
Yersinia pestis, the causative agent of plague, has killed millions throughout human history. Though...
The recent progress in immunoinformatics provided the basis for an accelerated development of target...
International audienceYersinia pestis, the agent of plague, is among the deadliest bacterial pathoge...
International audienceA single oral inoculation to mice of the live attenuated Yersinia pseudotuberc...
The gene encoding V antigen from Yersinia pestis was cloned into the plasmid expression vector pGEX-...
<div><h3>Background</h3><p>Plague is still a public health problem in the world and is re-emerging, ...
Plague is one of the most dangerous diseases and is caused by Yersinia pestis. Effective vaccine dev...
Abstract Background Yersinia pestis, the causative agent of plague, is a pathogen with a tremendous ...
AbstractLive plague vaccines have saved thousands of human lives in the 20th century and have contin...
Relatively recent advances in plague vaccinology have produced the recombinant fusion protein F1-V p...
Abstract. A single, subcutaneous, 30-mg dose of either a combination of the Yersinia pestis proteins...
International audienceImmunization with the live-attenuated Yersinia pseudotuberculosis VTnF1 strain...
<div><p>Background</p><p>No efficient vaccine against plague is currently available. We previously s...
International audienceWe evaluated the possibility of using Yersinia pseudotuberculosis as a live va...
Yersinia pestis is the etiologic agent of plague that has killed more than 200 million people throug...
Yersinia pestis, the causative agent of plague, has killed millions throughout human history. Though...
The recent progress in immunoinformatics provided the basis for an accelerated development of target...
International audienceYersinia pestis, the agent of plague, is among the deadliest bacterial pathoge...
International audienceA single oral inoculation to mice of the live attenuated Yersinia pseudotuberc...
The gene encoding V antigen from Yersinia pestis was cloned into the plasmid expression vector pGEX-...
<div><h3>Background</h3><p>Plague is still a public health problem in the world and is re-emerging, ...
Plague is one of the most dangerous diseases and is caused by Yersinia pestis. Effective vaccine dev...
Abstract Background Yersinia pestis, the causative agent of plague, is a pathogen with a tremendous ...
AbstractLive plague vaccines have saved thousands of human lives in the 20th century and have contin...
Relatively recent advances in plague vaccinology have produced the recombinant fusion protein F1-V p...
Abstract. A single, subcutaneous, 30-mg dose of either a combination of the Yersinia pestis proteins...